Pharvaris

Zug, Switzerland

Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.

May 2026

Post-IPO Equity

Top Investors

General AtlanticCormorant Asset ManagementVenrockForesite CapitalBain Capital Life Sciences

19,000+ verified contacts

Emails, phones & LinkedIn profiles

Who are Pharvaris's investors?

Pharvaris's investors include General Atlantic, Cormorant Asset Management, Venrock, Foresite Capital, Bain Capital Life Sciences.

Where is Pharvaris headquartered?

Pharvaris is headquartered in Zug, Switzerland.

What does Pharvaris do?

Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.

What stage is Pharvaris at?

Pharvaris is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated May 8, 2026.

MLA

"Pharvaris — Funding & Investors." VCBacked, May 8, 2026, https://www.vcbacked.co/company/pharvaris. Accessed June 3, 2026.

APA

VCBacked. (2026). Pharvaris — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/pharvaris

Wikipedia (cite web)

{{cite web |title=Pharvaris — Funding & Investors |url=https://www.vcbacked.co/company/pharvaris |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated May 8, 2026.